AREV Life Sciences Global Corp (AREVF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAREV Life Sciences Global Corp (AREVF) trades at $0.0005. AREV Life Sciences Global Corp. focuses on developing and selling functional ingredients, particularly CBD-infused products, targeting the natural health and nutraceutical markets. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for AREVF: AREVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
AREV Life Sciences Global Corp (AREVF) Healthcare & Pipeline Overview
AREV Life Sciences Global Corp. is a Canadian integrated life science company producing and distributing functional ingredients, including CBD-infused products and nutraceutical formulations, targeting the natural health, medical, and sports nutrition markets. The company focuses on addressing health issues such as sleep deprivation, anxiety, and pain management through its diverse product line.
What Is the Investment Thesis for AREVF?
AREV Life Sciences Global Corp. operates in the growing market for functional ingredients and CBD-infused products. The company's diverse product line targeting various health conditions presents a potential growth opportunity. However, the company's negative profit margin of -2940.4% and gross margin of -155.7% raise concerns about its financial sustainability. The high beta of 5.40 indicates significant volatility relative to the market. Key growth catalysts include expanding its product distribution and market reach. Investors should carefully consider the company's financial performance and market competition before investing.
Based on FMP financials and quantitative analysis
AREVF Key Highlights
Market Cap of $0.00B indicates a small company with limited resources.
- P/E Ratio of -1.87 suggests the company is not currently profitable.
- Profit Margin of -2940.4% indicates significant losses relative to revenue.
- Gross Margin of -155.7% shows the company's cost of goods sold exceeds its revenue.
- Beta of 5.40 suggests the stock is highly volatile compared to the market.
Who Are AREVF's Competitors?
AREVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ONC BeOne Medicines Ltd. | $361.65 | +1.00% | $38.7B | 96 5-pillar |
| DMRA Galecto, Inc. | $20.22 | -2.08% | $1.24B | 57 5-pillar |
| CGEM Cullinan Therapeutics, Inc. | $16.04 | +3.42% | $986M | 56 5-pillar |
| HITI High Tide Inc. | $2.73 | +3.80% | $240M | 35 5-pillar |
| LFMDP LifeMD, Inc. | $22.86 | +0.53% | $156M | — |
| PETS PetMed Express, Inc. | $1.33 | -2.21% | $28.4M | 32 5-pillar |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| KYNB Kyntra Bio, Inc. | $6.09 | -3.49% | $24.7M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AREVF's Key Strengths?
Diverse product line targeting various health conditions.
- Proprietary formulations for CBD-infused products.
- Established presence in the Canadian market.
- Offers white-label manufacturing services.
What Are AREVF's Weaknesses?
Negative profit margin and gross margin.
- High beta indicating significant volatility.
- Limited market capitalization.
- Dependence on the Canadian market.
What Are the Key Risks for AREVF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition in the nutraceutical and CBD markets could limit AREV's market share and profitability.
- Regulatory hurdles and changing regulations could impact the company's ability to market and sell its products.
- Fluctuations in the price of raw materials could increase the company's cost of goods sold and reduce its profit margins.
- Product recalls or liability claims could damage the company's reputation and financial performance.
- The company's negative profit margin and gross margin raise concerns about its financial sustainability.
What Are AREVF's Competitive Advantages?
- Proprietary formulations for CBD-infused products.
- Established presence in the Canadian market.
- Diverse product line targeting various health conditions.
- Manufacturing capabilities for white-label production.
What Does AREVF Do?
AREV Life Sciences Global Corp., established in 2005 and based in Coquitlam, Canada, operates as an integrated life science discovery company focused on the production and sale of functional ingredients. Originally incorporated as AREV NanoTec Brands Inc., the company rebranded in August 2021 to reflect its broader focus on life sciences. AREV specializes in CBD-infused products, including Canna-Mulsion and NaturVax anti-viral supplements, NaturRelax for sleep aid, and Natur Relief for pain and inflammation. The company also offers white-label cannabis products, THC products, cannabis skincare, medicinal oils, and edibles. These ingredients are designed for use in the natural health, medical, functional food, nutraceutical, sports nutrition, and bioceutical markets. AREV's product line addresses various health concerns, including sleep deprivation, insomnia, anxiety, pain, and inflammatory conditions. Additionally, AREV provides nutraceutical product formulations under the Bare brand and ready-to-use therapeutic food products under the SUS-TAINN brand, expanding its reach in the health and wellness sector.
What Products and Services Does AREVF Offer?
- Produces and sells functional ingredients.
- Develops and markets CBD-infused products.
- Offers anti-viral supplements under the NaturVax brand.
- Provides natural sleep aids under the NaturRelax brand.
- Offers anti-inflammatory and pain relief products under the Natur Relief brand.
- Manufactures white-label cannabis products.
- Develops nutraceutical product formulations under the Bare brand.
- Produces ready-to-use therapeutic food products under the SUS-TAINN name.
How Does AREVF Make Money?
- Develops and manufactures functional ingredients and CBD-infused products.
- Sells products through distributors and direct-to-consumer channels.
- Offers white-label manufacturing services to other companies.
- Generates revenue from the sale of its branded products and white-label services.
What Industry Does AREVF Operate In?
AREV Life Sciences Global Corp. operates within the specialty and generic drug manufacturing industry, which is experiencing growth driven by increasing demand for nutraceuticals and CBD-infused products. The market is competitive, with companies like AOXG, CNNXF, CWWBF, GBHPF, and GRVE vying for market share. The increasing acceptance of cannabis-based products for medicinal and recreational use is a significant trend, but regulatory hurdles and competition remain challenges.
Who Are AREVF's Key Customers?
- Consumers seeking natural health and wellness products.
- Distributors of nutraceuticals and functional foods.
- Companies in the natural health, medical, and sports nutrition markets.
- Businesses seeking white-label manufacturing services.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
AREV Life Sciences Global Corp operates in the Healthcare sector. It is headquartered in Coquitlam, CA. The company is led by CEO Michael C. Withrow. AREVF has traded publicly since 2019.
Key Financial Metrics
Return on equity for AREV Life Sciences Global Corp stands at 276.1%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -12.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -53.4%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
AREV Life Sciences Global Corp's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
AREVF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
AREVF Latest News
-
List of Companies Reaching Yearly Lows Tuesday
· Jul 23, 2019
AREVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AREVF.
Price Targets
Wall Street price target analysis for AREVF.
AREVF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for AREVF; grades run from A+ (80-100) to F (below 30).
Leadership: Michael C. Withrow
CEO
Michael C. Withrow serves as the CEO of AREV Life Sciences Global Corp. His background includes experience in the pharmaceutical and nutraceutical industries. Withrow has held various leadership positions in companies focused on developing and marketing innovative health and wellness products. He brings expertise in product development, regulatory affairs, and market strategy. His focus is on driving AREV's growth through strategic partnerships and product innovation.
Track Record: Under Michael Withrow's leadership, AREV Life Sciences Global Corp. has focused on expanding its product line and market reach. Key achievements include the development of new CBD-infused products and the establishment of partnerships with distributors. The company has also focused on enhancing its manufacturing capabilities and expanding its white-label services. However, the company's financial performance remains a challenge.
AREVF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that AREV Life Sciences Global Corp. may not meet the minimum financial standards or reporting requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in AREV Life Sciences Global Corp.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- The OTC Other tier indicates a higher risk of fraud or mismanagement.
- Lack of regulatory oversight increases the potential for market manipulation.
- The company's financial performance raises concerns about its long-term viability.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Determine the company's ownership structure and insider holdings.
- Monitor news and press releases for any red flags or material events.
- Consult with a financial advisor to assess the suitability of the investment.
- The company has been in operation since 2005.
- AREV has a diverse product line targeting various health conditions.
- The company offers white-label manufacturing services.
- AREV has a CEO with experience in the pharmaceutical and nutraceutical industries.
Common Questions About AREVF (Healthcare)
What do analysts say about AREVF stock?
There is currently no available analyst coverage or consensus on AREVF stock. Given its OTC listing and small market capitalization, the company may not be widely followed by analysts. Investors should conduct their own independent research and due diligence before investing in AREVF.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is limited and may not be fully accurate.
- OTC market investments carry higher risks.
- Analyst coverage is non-existent.